Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 1 4Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Active not recruiting 4Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 7

Conditions

Pancreatic Neoplasms 6Pancreatic Cancer Metastatic 1

Interventions

pembrolizumab 514Specimen Handling 382Carboplatin 372Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 303Cyclophosphamide 295Radiotherapy 255Paclitaxel 252Biopsy 235Gemcitabine 231Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 155Rituximab 152Fluorouracil 148venetoclax 143Docetaxel 143atezolizumab 141Drug Therapy 140Etoposide 139Doxorubicin 131Ipilimumab 126Radiosurgery 118Prednisone 117Lenalidomide 117Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × folfirinox × 1 year × Clear all
NCT04594772 2026-06-01

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

University of Cincinnati

Phase 2 Active not recruiting
32 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04589234 2026-05-14

Saltikva for Metastatic Pancreatic Cancer

Salspera LLC

Phase 2 Active not recruiting
60 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04469556 2026-02-20

PASS-01

University Health Network, Toronto

Phase 2 Completed
150 enrolled
Gastrointestinal

Pancreatic Cancer Metastatic

NCT05360732 2025-11-13

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Fox Chase Cancer Center

Phase 2 Active not recruiting
37 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07208539 2025-10-06

ZSPAC-14

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
77 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03563248 2025-10-01

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
168 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05132504 2025-07-18

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Baylor College of Medicine

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡